ISM5411 is designed to directly regulate the intestinal immune microenvironment so that the drug simultaneously reduces the gut inflammation seen in IBD while also promoting the repair of the ...
BenevolentAI ("the Company"), a pioneer in integrating artificial intelligence with biopharmaceutical development, today unveils a major strategic overhaul to return the Company to its founding ...